Camarda Valeria, Guerrini Remo, Kostenis Evi, Rizzi Anna, Calò Girolamo, Hattenberger Almut, Zucchini Marina, Salvadori Severo, Regoli Domenico
Department of Experimental and Clinical Medicine, Section of Pharmacology, via Fossato di Mortara 17-19, Ferrara, 44100 Ferrara, Italy.
Br J Pharmacol. 2002 Oct;137(3):311-4. doi: 10.1038/sj.bjp.0704895.
The cyclic peptide human urotensin II (U-II) has been recently recognized as the endogenous ligand of an orphan GPCR, subsequently named the UT receptor. No synthetic ligands are available for investigating this novel peptide-receptor system. A novel UT receptor ligand, [Orn(8)]U-II, was synthesized and evaluated in calcium functional assays performed on HEK293 cells expressing the recombinant rat and human UT receptor and in the rat aorta bioassay. [Orn(8)]U-II behaves as a full agonist (pEC(50) approximately equal 8) at both human and rat UT receptors in the FlipR calcium assay eliciting similar maximal effects as the natural ligand U-II. On the contrary, in the rat aorta bioassay, [Orn(8)]U-II behaves as a competitive and selective antagonist (pA(2)=6.56) showing however a small but consistent residual agonist activity. It is therefore proposed that [Orn(8)]U-II is a partial agonist at UT receptors.
环肽人尿紧张素II(U-II)最近被确认为一种孤儿G蛋白偶联受体(GPCR)的内源性配体,该受体随后被命名为UT受体。目前尚无用于研究这一新型肽-受体系统的合成配体。一种新型UT受体配体[Orn(8)]U-II被合成出来,并在对表达重组大鼠和人UT受体的HEK293细胞进行的钙功能测定以及大鼠主动脉生物测定中进行了评估。在FlipR钙测定中,[Orn(8)]U-II在人和大鼠UT受体上均表现为完全激动剂(pEC(50)约等于8),引发的最大效应与天然配体U-II相似。相反,在大鼠主动脉生物测定中,[Orn(8)]U-II表现为竞争性和选择性拮抗剂(pA(2)=6.56),不过显示出小但持续的残余激动剂活性。因此,有人提出[Orn(8)]U-II是UT受体的部分激动剂。